

Yawen Pan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3471713/publications.pdf>

Version: 2024-02-01

18
papers

207
citations

1040056

9
h-index

1058476

14
g-index

21
all docs

21
docs citations

21
times ranked

355
citing authors

#	ARTICLE	IF	CITATIONS
1	Expressions and significances of CTSL, the target of COVID-19 on GBM. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 599-608.	2.5	9
2	Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. <i>Molecular Neurobiology</i> , 2022, 59, 1262-1272.	4.0	12
3	CircTCF25 serves as a sponge for miR-206 to support proliferation, migration, and invasion of glioma via the Jak2/p-Stat3/CypB axis. <i>Molecular Carcinogenesis</i> , 2022, 61, 558-571.	2.7	2
4	Biochanin A Inhibits Glioblastoma Growth via Restricting Glycolysis and Mitochondrial Oxidative Phosphorylation. <i>Frontiers in Oncology</i> , 2021, 11, 652008.	2.8	8
5	OLFML2A Downregulation Inhibits Glioma Proliferation Through Suppression of Wnt/ β 2-Catenin Signaling. <i>Frontiers in Oncology</i> , 2021, 11, 717917.	2.8	4
6	Elevated CD44 expression predicts poor prognosis in patients with low-grade glioma. <i>Oncology Letters</i> , 2019, 18, 3698-3704.	1.8	17
7	<p>Overexpression of HOXC6 promotes cell proliferation and migration via MAPK signaling and predicts a poor prognosis in glioblastoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8167-8179.	1.9	15
8	Downregulation of microRNA-374a predicts poor prognosis in human glioma. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 2077-2084.	1.8	5
9	SLC1A2 mediates refractory temporal lobe epilepsy with an initial precipitating injury by targeting the glutamatergic synapse pathway. <i>IUBMB Life</i> , 2019, 71, 213-222.	3.4	13
10	The quality assessment of clinical practice guidelines for intracranial aneurysms: a systematic appraisal. <i>Neurosurgical Review</i> , 2018, 41, 629-639.	2.4	2
11	Solitary subdural osteoma: A case report and literature review. <i>Clinical Neurology and Neurosurgery</i> , 2018, 172, 87-89.	1.4	7
12	Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2017, 133, 193-201.	2.9	32
13	Comprehensive analysis of a microRNA expression profile in pediatric medulloblastoma. <i>Molecular Medicine Reports</i> , 2017, 15, 4109-4115.	2.4	17
14	Integrated mRNAseq and microRNAseq data analysis for grade III gliomas. <i>Molecular Medicine Reports</i> , 2017, 16, 7468-7478.	2.4	12
15	The analysis of correlative factors affecting long-term outcomes in patients with Solid Cerebellar Hemangioblastomas. <i>Clinical Neurology and Neurosurgery</i> , 2016, 150, 59-66.	1.4	13
16	Myeloperoxidase Nuclear Imaging for Epileptogenesis. <i>Radiology</i> , 2016, 278, 822-830.	7.3	24
17	Risk Factors for Postoperative Fibrinogen Deficiency after Surgical Removal of Intracranial Tumors. <i>PLoS ONE</i> , 2015, 10, e0144551.	2.5	12
18	Glioblastoma multiforme in the brainstem in a young adult. <i>Clinical Neurology and Neurosurgery</i> , 2014, 124, 175-178.	1.4	3